Journal of Oncological Sciences最新文献_第2页

The Incidental Diagnosis of Lung Cancer Through Chest Tomography During the COVID-19 Pandemic 新冠肺炎大流行期间胸部断层扫描对肺癌的偶发诊断

Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2023-98748

Yakup DÜZKÖPRÜ, Gökşen İNANÇ İMAMOĞLU, Ebru ÇILBIR, Abdülkadir KOÇANOĞLU, Özlem DOĞAN, Yeliz AKTÜRK, Hayriye ŞAHİNLİ, Tülay EREN, Yunus GÜRBÜZ, Doğan YAZILITAŞ, Mustafa ALTINBAŞ

{"title":"The Incidental Diagnosis of Lung Cancer Through Chest Tomography During the COVID-19 Pandemic","authors":"Yakup DÜZKÖPRÜ, Gökşen İNANÇ İMAMOĞLU, Ebru ÇILBIR, Abdülkadir KOÇANOĞLU, Özlem DOĞAN, Yeliz AKTÜRK, Hayriye ŞAHİNLİ, Tülay EREN, Yunus GÜRBÜZ, Doğan YAZILITAŞ, Mustafa ALTINBAŞ","doi":"10.37047/jos.2023-98748","DOIUrl":"https://doi.org/10.37047/jos.2023-98748","url":null,"abstract":": This study aims to determine the frequency of incidental lung cancers detected during chest computed tomography (CT) scans performed for guiding the diagnosis or treatment of coronavirus disease-2019 (COVID-19). Material and Methods: In this single-center retrospective study, the chest CT scans taken during the beginning of COVID-19 pneumonia (mostly pre-vaccination era) between April 2020 and December 2020 were examined. Patients who were younger than 18 years and those with a prior history of cancer were excluded. Moreover, the clinicopathological factors and radiologic findings of those patients with pulmonary nodule size on CT ≥ 3 mm or masses were recorded. Results: We assessed the CT scans of 2994 patients. A pulmonary nodule ≥ 3 mm or a mass was detected in 473 patients, while nine of them were diagnosed with lung cancer. The median age of lung cancer patients was 65 years (48-71 years). The most common subtype of lung cancer was adenocarcinoma (44.4%), followed by squamous cell carcinoma (33.3%) and small cell lung cancer (22.2%). Furthermore, all patients were diagnosed at the non-metastatic stage. Conclusion: Our study showed that early-stage lung cancers were detected incidentally on CT scans in suspected COVID-19 pneumonia patients. While the COVID-19 pandemic resulted in significant mortality worldwide, early diagnosis and treatment of these cases can save several lives.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134889468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Professional Seniority on Total Neoadjuvant Treatment Approach for Locally Advanced Rectal Cancer 职业年资对局部晚期直肠癌新辅助治疗方法的影响

Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2023-96807

E. Şenocak Taşçı, E. Aytaç, Mirac Ajredini, Arda Ulaş Mutlu, I. Yıldız, Leyla Özer

{"title":"Impact of Professional Seniority on Total Neoadjuvant Treatment Approach for Locally Advanced Rectal Cancer","authors":"E. Şenocak Taşçı, E. Aytaç, Mirac Ajredini, Arda Ulaş Mutlu, I. Yıldız, Leyla Özer","doi":"10.37047/jos.2023-96807","DOIUrl":"https://doi.org/10.37047/jos.2023-96807","url":null,"abstract":"Objective: Total neoadjuvant therapy (TNT) integrates whole planned systemic chemotherapy within standard neoadjuvant protocols either before or after radiotherapy for locally advanced rectal cancer (LARC). However, the preference for neoadjuvant treatment type may vary among medical oncologists. We aimed to evaluate the impact of professional seniority on the TNT approach for LARC. Material and Methods: We presented a 20-item questionnaire to medical oncologists as a cross-sectional survey. The evaluation was stratified based on position: early-career oncologists (ECOs) and seniors. Results: We included 189 (62.4% ECOs) medical oncologists. Seniors significantly preferred using endorectal ultrasound as a staging tool (p=0.039). 65.6% of the participants preferred long-course chemoradiation. The most common denominators for TNT were external sphincter invasion, threatened circumferential resection margin (CRM), and clinical stage. ECOs and seniors preferred short-course radiotherapy (p=0.009) and long-course chemoradiotherapy (p=0.041), respectively, as the index step of TNT. Furthermore, 57% of the physicians preferred to monitor treatment response for TNT at 8-week periods. Approximately 47.1% of the participants reported pathological complete response (pCR) rates between 25% and 50% with TNT. The physicians who prefer to administer adjuvant treatment after TNT completion make individualized decisions when surgical pathology reveals non-pCR, CRM, and lymph node involvement. Furthermore, 88% of the senior medical oncologists and 76.3% of the ECOs agreed that TNT should be the standardized neoadjuvant treatment approach for LARC. Conclusion: TNT for LARC is well accepted among medical oncologists, and professional seniority seems to affect its clinical application.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69825067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of Inflammatory Markers with Treatment Response in Immune Checkpoint Inhibitors 免疫检查点抑制剂中炎症标志物与治疗反应的关联

Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2023-99441

Murat BARDAKÇI, Öznur BAL, Fahriye Tuğba KÖŞ, Derya DEMİRTAŞ ESMER, Emre HAFIZOĞLU, Hilal KARAKAŞ, Muhammed Bülent AKINCI, Bülent YALÇIN

引用次数: 0

A Peritoneal Granulomatous Lesion with Dense Histiocytic Infiltration Due to Nivolumab Treatment 纳武单抗治疗引起的腹膜肉芽肿病变伴致密组织细胞浸润

Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2023-98050

Bilgin DEMİR, Ali AYTAÇ, İbrahim METEOĞLU, Sabri BARUTCA

引用次数: 0

Association of Immunoscore, CD73 Expression and 53BP1 Expression with Neoadjuvant Chemoradiotherapy Efficacy in Patients with Locally Advanced Rectal Cancer 局部晚期直肠癌患者免疫评分、CD73表达和53BP1表达与新辅助放化疗疗效的关系

Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2022-94374

O. Sütçüoğlu, Mehmet Arda Inan, A. Üner, Gozde Savas, H. Bora, A. Özet, N. Günel, N. Akyürek, O. Yazıcı, N. Özdemir

引用次数: 0

Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib 瑞非尼治疗转移性结直肠癌患者黏液组织学的预后意义

Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2022-94250

R. Arıkan, Hilal SAĞIROĞLU ÜSTÜN, N. Demircan, S. Isik, T. Akın Telli, Alper Yaşar, A. Celebı, N. Majidova, Nadiye Sever, Ç. Çelikel, M. Sari, Özlem Ercelep, Osman Köstek, I. V. Bayoglu

{"title":"Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib","authors":"R. Arıkan, Hilal SAĞIROĞLU ÜSTÜN, N. Demircan, S. Isik, T. Akın Telli, Alper Yaşar, A. Celebı, N. Majidova, Nadiye Sever, Ç. Çelikel, M. Sari, Özlem Ercelep, Osman Köstek, I. V. Bayoglu","doi":"10.37047/jos.2022-94250","DOIUrl":"https://doi.org/10.37047/jos.2022-94250","url":null,"abstract":"ABS TRACT Objective: Prognostic factors for regorafenib therapy have not been fully defined. Mucinous adenocarcinoma (MAC) is a distinct subtype of colorectal cancer (CRC). We investigated the significance of mucinous histology in patients treated with regorafenib for metastatic CRC (mCRC). Material and Methods: In this retrospective study, patients were stratified according to the presence of mucinous histology; >1% extracellular mucin was defined as mucinous component adenocarcinoma (MCAC), and containing no mucin was defined as non-MAC. The prognostic significance of mucinous histology for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Results: A total of 103 patients were included, including 20 (19.4%) patients with MCAC and 83 (80.6%) patients with non-MAC. The median follow-up time was 8.6 months (range 1.8-31.6 months). The median PFS was lower in cases with MCAC than those with non-MAC (3.2 months vs. 3.6 months, respectively, p=0.01). Median OS was lower in MCAC patients than in non-MAC patients (4.3 months vs. 9.6 months, respectively, p=0.008). In multivariate analyses, mucinous histology was an independent risk factor [hazard ratio (HR): 2.2, p=0.003] for PFS and Eastern Cooperative Oncology Group-Performance Status (HR: 2.2, p=0.01), cancer antigen 19-9 (HR: 1.7, p=0.03), and mucinous histology (HR: 1.9, p=0.02) were independent risk factors for OS. Conclusion: This study revealed the prognostic value of mucinous histology in mCRC patients treated with regorafenib. Consideration of histologic features may be helpful in selecting patients for regorafenib therapy.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience 不可切除的肝细胞癌和索拉非尼治疗的预后因素:一个真实的经验

Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2023-96148

C. Erol, M. Bardakçi, M. Hızal, S. Kahraman, E. Yekedüz, D. Güven, M. Aykan, Recep Ak, Öztürk Ateş, D. Şener Dede, M. Akinci, N. Karadurmuş, Öznur Bal, Y. Ürün, Ş. Yalçın, B. Yalcin, M. Şendur

{"title":"Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience","authors":"C. Erol, M. Bardakçi, M. Hızal, S. Kahraman, E. Yekedüz, D. Güven, M. Aykan, Recep Ak, Öztürk Ateş, D. Şener Dede, M. Akinci, N. Karadurmuş, Öznur Bal, Y. Ürün, Ş. Yalçın, B. Yalcin, M. Şendur","doi":"10.37047/jos.2023-96148","DOIUrl":"https://doi.org/10.37047/jos.2023-96148","url":null,"abstract":"ABS TRACT Objective: Sorafenib is the first targeted therapy for patients with advanced hepatocellular carcinoma (HCC). This multicenter study primarily aimed to assess real-life experiences of sorafenib in patients with advanced HCC in Türkiye and to determine the prognostic factors. Material and Methods: Patients treated with sorafenib for HCC treatment were included in a retrospective collection of demographic, clinical, and laboratory data. Overall survival (OS) and progression-free survival (PFS), safety data, and prognostic factors were analyzed. Results: A total of 147 patients receiving sorafenib from six tertiary oncology centers were included. Approximately 88.4% and 11.6% of patients were Child-Pugh (CP) classes A and B, respectively. The median PFS was 5.1 (95% CI, 4.3 to 5.9) and 2.9 months (95% CI, 2.3 to 3.5), and OS was 9.8 (95% CI, 6.4 to 13.2) and 5.3 months (95% CI, 4.1 to 6.5) in patients with CP-A and CP-B, respectively. There was a difference in OS between CP-A and B (p=<0.001). The most common adverse event was diarrhea (19.7%, Grade 1-2; 6.8%, Grade 3). The eastern cooperative oncology group (ECOG) performance score, CP score, neutrophil-lymphocyte ratio (NLR), and alpha-fetoprotein (AFP) values were found to be independent prognostic factors. Conclusion: OS and PFS were similar in routine clinical practice compared to Phase III pivotal SHARP and Asia-Pacific trials. The median survival was longer in those with a better ECOG performance score, CP-A, and lower NLR and AFP levels.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69825437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nab-Paclitaxel-Loaded Poly (Lactic-Co-Glycolic Acid) Nanoparticles as Microtubule B-Tubulin Stabilizer in the Management of Pancreatic Cancer nab -紫杉醇负载聚乳酸-羟基乙酸纳米颗粒作为微管b-微管蛋白稳定剂在胰腺癌治疗中的应用

Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2022-94097

Bryan Gervais de de LIYIS, Viona MARESKA, Celine Aurelia AHMAD, Alexandria Cahyaputri WINDIARTO, Agung Wiwiek INDRAYANI

引用次数: 0

A Novel Tumor Marker for Anaplastic Lymphoma Kinase (+) Lymphoma: Beta-Human Chorionic Gonadotropin 间变性淋巴瘤激酶(+)淋巴瘤的新肿瘤标志物:β -人绒毛膜促性腺激素

Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2021-84655

K. Moral, Esra Seyhan, Dilan Yağmur Kutlay, S. Akın

引用次数: 0

Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer 雌激素受体阳性绝经前乳腺癌患者雄激素受体表达的预后价值

Journal of Oncological Sciences Pub Date : 2023-01-01 DOI: 10.37047/jos.2022-94227

H. Yıldırım, M. Üner, Tuğba YILDIRAN ÖZMEN, E. Chalabiyev, D. Güven, F. Kuş, A. Akyildiz, F. Yilmaz, S. Yasar, Y.N. Evlendi, Ö. Dizdar, Ş. Yalçın, A. Üner, S. Aksoy

引用次数: 0